| Patented Medicine Prices Review Board Canada | news releases
Sales of patented medicines in Canada were $22.1 billion in 2024, a 10.9% increase over the year before.
| Patented Medicine Prices Review Board Canada | news releases
The latest edition of the PMPRB CompassRx report shows that prescription drug expenditure for public drug plans grew by 7.4% in 2022/23 to reach $14.1 billion, compared to $13.2 billion in 2021/22.
| Patented Medicine Prices Review Board Canada | news releases
PMPRB releases new Guidelines to monitor and review drug prices
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board published the 9th edition of its annual Meds Entry Watch report today.
| Patented Medicine Prices Review Board Canada | news releases
Chairperson of the PMPRB, Mr. Thomas Digby has stepped down from his role, effective March 6, 2025.
| Patented Medicine Prices Review Board Canada | news releases
Report explores the drivers of growth in prescription drug costs for private drug plans
| Patented Medicine Prices Review Board Canada | news releases
86 new patented medicines were reported to the PMPRB in 2023
| Patented Medicine Prices Review Board Canada | news releases
The latest edition of Meds Pipeline Monitor provides stakeholders with a list of new medicines in the late stages of clinical evaluation that may significantly impact clinical practice or drug spending in the coming years.
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board published the 8th edition of its annual Meds Entry Watch report today.
| Patented Medicine Prices Review Board Canada | news releases
The Honourable Mark Holland, Federal Minister of Health, today tabled the 2022 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the Senate and the House of Commons.
